---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-093782"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2026-08-11T12:10:25+00:00"
generated_at: "2026-08-11T12:15:38.785669+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics Q2 2026: Cash $11.3M, VIRAGE2 first patients dosed

## Summary
- Cash and cash equivalents $11.3M as of June 30, 2026; runway into Q1 2027.
- G&A expenses down 82% YoY to $2.0M from $11.2M; prior-year $9.2M contingent consideration adjustment.
- R&D expenses down 35% to $1.3M from $2.0M; H1 2026 net loss $5.3M.
- First patients dosed in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment completion expected H2 2026.
- Proposed Phase 2/3 retinoblastoma trial design completed; FDA discussion planned Q3 2026.

## SEC filing metadata
- accession: 0001104659-26-093782
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2026-08-11T12:10:25+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/0001104659-26-093782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-093782
- JSON: https://secwatch.observer/filing/0001104659-26-093782.json
- Plain text: https://secwatch.observer/filing/0001104659-26-093782.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.